Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of recent ratings for Milestone Pharmaceuticals and Chugai Pharmaceutical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Milestone Pharmaceuticals | 1 | 1 | 3 | 1 | 2.67 |
| Chugai Pharmaceutical | 0 | 2 | 1 | 1 | 2.75 |
Milestone Pharmaceuticals currently has a consensus target price of $7.25, indicating a potential upside of 571.30%. Given Milestone Pharmaceuticals’ higher possible upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Chugai Pharmaceutical.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
| Chugai Pharmaceutical | 35.09% | 23.71% | 19.96% |
Risk and Volatility
Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Insider & Institutional Ownership
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Milestone Pharmaceuticals and Chugai Pharmaceutical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Milestone Pharmaceuticals | $1.55 million | 86.75 | -$63.06 million | ($0.69) | -1.57 |
| Chugai Pharmaceutical | $8.41 billion | 8.68 | $2.91 billion | $0.92 | 24.12 |
Chugai Pharmaceutical has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Chugai Pharmaceutical beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
